154 related articles for article (PubMed ID: 22068464)
1. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T; Sakano S; Matsuda K; Kamiryo Y; Yamamoto N; Kaneda Y; Nasu T; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Imoto K; Matsuyama H
Int J Clin Oncol; 2013 Feb; 18(1):62-7. PubMed ID: 22068464
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
6. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
[TBL] [Abstract][Full Text] [Related]
7. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
8. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Angelergues A; Efstathiou E; Gyftaki R; Wysocki PJ; Lainez N; Gonzalez I; Castellano DE; Ozguroglu M; Carbonero IG; Flechon A; Borrega P; Guillot A; Balea BC; Le Moulec S; Esteban E; Munarriz J; Rubio G; Birtle AJ; Delanoy N; Bellmunt J; Oudard S
Clin Genitourin Cancer; 2018 Aug; 16(4):e777-e784. PubMed ID: 29550200
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.
Kamiya N; Suzuki H; Ueda T; Sato N; Nakatsu H; Mikami K; Sato N; Nomura K; Akakura K; Okano T; Ooki T; Naya Y; Ota S; Masai M; Ichikawa T
Int J Clin Oncol; 2014 Feb; 19(1):157-64. PubMed ID: 23299278
[TBL] [Abstract][Full Text] [Related]
11. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
13. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
15. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Yu EY; Gulati R; Telesca D; Jiang P; Tam S; Russell KJ; Nelson PS; Etzioni RD; Higano CS
J Clin Oncol; 2010 Jun; 28(16):2668-73. PubMed ID: 20421544
[TBL] [Abstract][Full Text] [Related]
16. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
18. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K
Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Thomas C; Brandt MP; Baldauf S; Tsaur I; Frees S; Borgmann H; Jäger W; Bartsch G; Schneider M; Dotzauer R; Neisius A; Haferkamp A
Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
